

# Fermentation and cardiovascular risk factors

<b>Submission date</b> 07/06/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 02/08/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 07/02/2012	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Denise Robertson

**Contact details**  
Biomedical and Molecular Sciences  
University of Surrey  
Guildford  
United Kingdom  
GU2 7XH

## Additional identifiers

**Protocol serial number**  
NS1

## Study information

**Scientific Title**

### Study objectives

That consuming a fermentable carbohydrate will improve indices of insulin sensitivity in individuals with insulin resistance.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Central Office of Research Ethics Committees (COREC) and the University of Surrey Ethics Committee, approved on 26th June 2006 (REC ref: O6/Q1909/30)

**Study design**

Randomised, parallel, single-blind dietary intervention.

**Primary study design**

Interventional

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Type 2 diabetes/ obesity

**Interventions**

Dietary supplementation with either 0 g, 20 g or 40 g resistant starch per day for 12 weeks.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

resistant starch

**Primary outcome(s)**

Insulin sensitivity will be assessed before and after the 12-week intervention by the following:

1. Euglycaemic-hyperinsulinaemic clamp
2. Liver fat content measured by Magnetic Resonance Imaging [MRI]

**Key secondary outcome(s)**

The following outcomes are being measured before and after the 12-week intervention:

1. Endothelial function, assessed by Pulse Wave Velocity (PWV) and 24-hour blood pressure recordings
2. Blood inflammatory markers

**Completion date**

30/10/2008

**Eligibility****Key inclusion criteria**

1. Healthy
2. Fasting insulin >60 pmol/l
2. Male and female 18-60 years

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

60 years

**Sex**

All

**Key exclusion criteria**

1. Cardiovascular or endocrine diseases
2. Medication likely to affects either lipid or glucose metabolism

**Date of first enrolment**

01/11/2006

**Date of final enrolment**

30/10/2008

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Biomedical and Molecular Sciences**

Guildford

United Kingdom

GU2 7XH

**Sponsor information****Organisation**

University of Surrey (UK)

ROR

<https://ror.org/00ks66431>

## Funder(s)

**Funder type**

Industry

**Funder Name**

National Starch and Chemical Company (International)

## Results and Publications

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/04/2010		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes